Regulatory Amgen’s BiTE for lung cancer backed for EU approval PharmaphorumAmgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 30, 2026) Pharmaphorum Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP. RegulatoryOncologyRead full story Post navigation Previous: Trustworthy AI in clinical oversightNext: The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
